Royal DSM To Make Equity Investment In Amyris With the Purpose of Establishing a Long-Term Relationship
08 Maggio 2017 - 2:30PM
Amyris, Inc. (Nasdaq:AMRS)
, the industrial
bioscience company, and Koninklijke DSM N.V. (Royal DSM)
(AEX:DSM.AS)
, the global science-based company active in
health, nutrition and materials, today announced that they have
agreed for DSM to make an equity investment in Amyris. At the same
time, the companies will enter into a development cooperation
focused on products for the global health and nutrition markets
(including vitamins and other nutritional
ingredients).
Amyris’ technology supports DSM’s strategic markets in health,
nutrition, and materials as well as a growing consumer shift to
(bio-) natural-like products derived from sustainable sources. For
Amyris, DSM’s channels and market access and keen understanding in
selecting the right products for the animal nutrition, human
nutrition, and consumer health markets provide strategic value.
Equity InvestmentDSM has agreed to make an
initial equity investment in Amyris of US$25 million, translating
into a shareholding of ~12%. Subject to the satisfaction of certain
conditions, DSM may invest an additional US$25 million in Amyris.
The first tranche is expected to close on Thursday, 11 May 2017,
with a second tranche, if approved by DSM’s Managing Board,
expected to close within 90 days of the closing of the first
tranche. As part of this investment, DSM will gain one board seat
upon the closing of each tranche.
As part of the agreement, DSM and Amyris have agreed to focus on
a number of short- to medium-term product development &
production opportunities in vitamins and other nutritional
ingredients.
“We are very excited about DSM’s strategic focus in health and
nutrition markets and its commitment to sustainable sourcing and
production of better-performing products,” said John Melo, Amyris
President & CEO. “The Amyris technology platform and potential
synergy can lead to significant cost improvements for DSM while
accelerating Amyris’s market access. We expect this will lead to
incremental revenue in 2017, growing annually based on the number
of products we develop in our partnership and our pace of
delivery.”
“Amyris has a unique yeast-based strain engineering platform
that is very complementary to DSM’s capabilities in this area and
will create great synergy with DSM’s know-how in fermentation,
downstream process development and large-scale manufacturing,” said
Chris Goppelsroeder, President & CEO of DSM Nutritional
Products. “Working closely together with Amyris and leveraging
DSM’s route-to-market, will accelerate our innovation towards
cost-effective, fermentation-based processes for both existing and
new products."
Terms of the private placement and related agreements are more
fully disclosed in the Form 8-K filed by Amyris today with the
Securities and Exchange Commission, available free of charge at
sec.gov.
DSM – Bright Science. Brighter
Living.™ Royal DSM is a global science-based company
active in health, nutrition and materials. By connecting its unique
competences in Life Sciences and Materials Sciences DSM is driving
economic prosperity, environmental progress and social advances to
create sustainable value for all stakeholders simultaneously. DSM
delivers innovative solutions that nourish, protect and improve
performance in global markets such as food and dietary supplements,
personal care, feed, medical devices, automotive, paints,
electrical and electronics, life protection, alternative energy and
bio-based materials. DSM and its associated companies deliver
annual net sales of about €10 billion with approximately
25,000 employees. The company is listed on Euronext Amsterdam. More
information can be found at www.dsm.com.
About AmyrisAmyris is the integrated renewable
products company that is enabling the world’s leading brands to
achieve sustainable growth. Amyris applies its innovative
bioscience solutions to convert plant sugars into hydrocarbon
molecules and produce specialty ingredients and consumer products.
The company is delivering its No Compromise® products across a
number of markets, including specialty and performance chemicals,
flavors and fragrances, cosmetics ingredients, pharmaceuticals, and
nutraceuticals. More information about the company is available at
www.amyris.com.
DSM Forward-Looking StatementsThis press
release may contain forward-looking statements with respect to
DSM’s future (financial) performance and position. Such statements
are based on current expectations, estimates and projections of DSM
and information currently available to the company. DSM cautions
readers that such statements involve certain risks and
uncertainties that are difficult to predict and therefore it should
be understood that many factors can cause actual performance and
position to differ materially from these statements. DSM has no
obligation to update the statements contained in this press
release, unless required by law. The English language version of
the press release is leading.
Amyris Forward-Looking StatementsThis release
contains forward-looking statements regarding Amyris, and any
statements regarding Amyris other than statements of historical
facts could be deemed to be forward-looking statements. These
forward-looking statements include, among other things, statements
regarding future events (such as the anticipated establishment of a
long-term relationship between Amyris and DSM, including the
expected entry into a development cooperation focused on products
for the global health and nutrition markets, the anticipated
closing of the first tranche of the financing referenced above,
including the timing thereof, the expected closing of a second
tranche of financing, including the timing thereof, and anticipated
acceleration of Amyris’s market access, and expected revenue and
revenue growth in 2017 and beyond, resulting from the partnership
with DSM) that involve risks and uncertainties. These statements
are based on management's current expectations and actual results
and future events may differ materially due to risks and
uncertainties, including risks related to manufacturing capacity at
Amyris’s Brotas facility, delays or failures in development,
production and commercialization of products, liquidity and ability
to fund capital expenditures, Amyris’s reliance on third parties to
achieve its goals, and other risks detailed in the “Risk Factors”
section of Amyris’s annual report on Form 10-K filed on April 17,
2017. Amyris disclaims any obligation to update information
contained in these forward-looking statements whether as a result
of new information, future events, or otherwise.
Amyris, the Amyris logo and No Compromise are registered
trademarks of Amyris, Inc. All other trademarks are trademarks of
their respective owners.
For more
information: |
|
DSM Corporate
Communications |
Amyris, Inc. |
Stephen Hufton |
Peter
DeNardo |
tel. +31 (0) 45 578
2017 |
tel.: +1 (510)
740-7481 |
e-mail: media.contacts@dsm.com
|
e-mail:
investor@amyris.com |
|
pr@amyris.com
|
|
|
DSM Investor
Relations |
|
Dave Huizing |
|
tel.: +31 (0) 45 578
2864 |
|
e-mail:
dave.huizing@dsm.com |
|